Advertisement
DHR vs TMO
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- Both DHR and TMO operate in the life sciences and diagnostics sector, providing essential tools and instruments for research, healthcare, and biopharma applications.
- As of July 17, 2026, DHR traded near $203.83 with a year-to-date return of approximately 10.59%, while TMO closed at $532.48 with a year-to-date return of about 7.92%.
- DHR is scheduled to report second-quarter 2026 results on July 21, 2026, followed by TMO on July 23, 2026, creating near-term catalysts for both stocks.
- Recent market activity shows TMO with stronger one-year returns (+25.75%) compared to DHR (+5.41%), reflecting differences in momentum and sector positioning.
- Both companies pursue growth through acquisitions and operational efficiency, with DHR emphasizing diagnostics expansion and TMO focusing on capital deployment including share repurchases.
- Relative performance highlights trade-offs in stability versus growth exposure within the same broad healthcare equipment and supplies industry.
Introduction
Investors and traders often compare DHR and TMO due to their prominent roles in the life sciences tools and diagnostics space. Both companies supply critical instrumentation, reagents, and services that support research, clinical testing, and biopharmaceutical development. This comparison appeals to those seeking exposure to healthcare innovation and laboratory infrastructure trends. Market participants evaluating relative performance, sector exposure, and upcoming earnings may find the analysis useful for assessing positioning within a shared competitive landscape. The review draws on recent market data and company developments to highlight observable contrasts without forward-looking speculation.
DHR Overview and Recent Performance
Danaher Corporation operates through segments focused on life sciences, diagnostics, and environmental and applied solutions, delivering precision instruments and consumables to laboratories and healthcare providers worldwide. In recent market activity, the stock has traded in a range influenced by broader healthcare sector dynamics and anticipation surrounding its second-quarter earnings release scheduled for July 21, 2026. Year-to-date returns reached approximately 10.59% as of mid-July 2026, outpacing the S&P 500 in that period, while the one-year return stood at about 5.41%. Recent developments include continued integration of prior acquisitions aimed at strengthening diagnostics capabilities. Sentiment has reflected measured optimism tied to operational execution and exposure to biopharma research demand, tempered by general market volatility in the healthcare equipment space.
TMO Overview and Recent Performance
DHR and TMO are companies in the life sciences and diagnostics sector of healthcare, but DHR has historically been more diversified in terms of the services it provides and industries. In recent years, it has separated itself from certain subsidiaries. The companies have been on a wild ride throughout the pandemic, with promising opportunities to play a role in the battle against the virus, but they have also shared in the uncertainty and struggles that other industries have been due to closures. Both have done extremely well in recent quarters providing life science products and solutions to the healthcare industry and governments. DHR made two extremely profitable acquisitions just prior to the pandemic that put it in a prime position for revenue growth; namely Cepheid, which has churned out Covid test kits, and Cytiva, which used to be GE’s biopharma subsidiary. They are now extremely similar in size and function. Both are likely to remain indispensable in the new healthcare landscape for several years.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 2 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 5 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -6.10% price change this week, while TMO (@Medical Specialties) price change was +5.36% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.33%. For the same industry, the average monthly price growth was +3.76%, and the average quarterly price growth was +2.79%.
Reported Earning Dates
DHR is expected to report earnings on Oct 27, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-0.33% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | TMO | DHR / TMO | |
| Capitalization | 135B | 213B | 63% |
| EBITDA | 7.08B | 11.7B | 60% |
| Gain YTD | -15.555 | -1.034 | 1,505% |
| P/E Ratio | 34.31 | 30.80 | 111% |
| Revenue | 24.8B | 45.2B | 55% |
| Total Cash | N/A | 1.12B | - |
| Total Debt | 18.5B | 43.2B | 43% |
DHR | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 80 | 62 | |
PRICE GROWTH RATING 1..100 | 59 | 45 | |
P/E GROWTH RATING 1..100 | 69 | 32 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (6) in the Medical Specialties industry is in the same range as TMO (12). This means that DHR’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as DHR (100). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as DHR (80). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's Price Growth Rating (45) in the Medical Specialties industry is in the same range as DHR (59). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's P/E Growth Rating (32) in the Medical Specialties industry is somewhat better than the same rating for DHR (69). This means that TMO’s stock grew somewhat faster than DHR’s over the last 12 months.
| DHR | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 47% | 1 day ago 64% |
| Stochastic ODDS (%) | 1 day ago 61% | 1 day ago 54% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 56% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 61% |
| Advances ODDS (%) | 1 day ago 54% | 1 day ago 61% |
| Declines ODDS (%) | 4 days ago 61% | 4 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 51% | 1 day ago 59% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.